Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | neuropeptide receptor A26 | 0.0448 | 1 | 1 |
Echinococcus granulosus | dipeptidyl aminopeptidaseprotein | 0.0182 | 0.335 | 0.335 |
Echinococcus multilocularis | histone acetyltransferase MYST2 | 0.0055 | 0.0167 | 0.0167 |
Echinococcus granulosus | neuropeptide receptor A26 | 0.0448 | 1 | 1 |
Echinococcus granulosus | endonuclease exonuclease phosphatase | 0.019 | 0.3548 | 0.3548 |
Leishmania major | dipeptidyl-peptidase 8-like serine peptidase, putative,serine peptidase, Clan SC, Family S9B | 0.0061 | 0.0325 | 1 |
Echinococcus granulosus | Dipeptidyl peptidase 9 | 0.0061 | 0.0325 | 0.0325 |
Schistosoma mansoni | hypothetical protein | 0.0171 | 0.308 | 0.5025 |
Loa Loa (eye worm) | MBCTL1 | 0.0055 | 0.0167 | 0.0499 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.0049 | 0.0028 | 0.0084 |
Toxoplasma gondii | dipeptidyl peptidase iv (dpp iv) n-terminal region domain-containing protein | 0.0061 | 0.0325 | 0.0728 |
Echinococcus granulosus | suppression of tumorigenicity 18 protein | 0.0055 | 0.0167 | 0.0167 |
Trypanosoma cruzi | dipeptidyl-peptidase 8-like serine peptidase | 0.0061 | 0.0325 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.0049 | 0.0028 | 0.0028 |
Brugia malayi | prolyl oligopeptidase family protein | 0.0182 | 0.335 | 1 |
Echinococcus granulosus | mitogen activated protein kinase | 0.0049 | 0.0028 | 0.0028 |
Schistosoma mansoni | dipeptidyl-peptidase 9 (S09 family) | 0.0061 | 0.0325 | 0.0531 |
Brugia malayi | MAP kinase sur-1 | 0.0049 | 0.0028 | 0.0084 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.0049 | 0.0028 | 0.0028 |
Echinococcus multilocularis | Dipeptidyl peptidase 9 | 0.0061 | 0.0325 | 0.0325 |
Echinococcus multilocularis | dipeptidyl aminopeptidaseprotein | 0.0182 | 0.335 | 0.335 |
Echinococcus multilocularis | neuropeptide s receptor | 0.0448 | 1 | 1 |
Schistosoma mansoni | subfamily S9B unassigned peptidase (S09 family) | 0.0182 | 0.335 | 0.5466 |
Schistosoma mansoni | hypothetical protein | 0.0293 | 0.6129 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0049 | 0.0028 | 0.5 |
Toxoplasma gondii | 1,3-beta-glucan synthase component protein | 0.0212 | 0.4108 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0049 | 0.0028 | 0.5 |
Trypanosoma brucei | serine peptidase, Clan SC, Family S9B | 0.0061 | 0.0325 | 1 |
Echinococcus granulosus | geminin | 0.0171 | 0.308 | 0.308 |
Loa Loa (eye worm) | STAT protein | 0.0159 | 0.2766 | 0.8258 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0049 | 0.0028 | 0.5 |
Trypanosoma brucei | Dipeptidyl-peptidase 8-like, putative | 0.0061 | 0.0325 | 1 |
Loa Loa (eye worm) | prolyl oligopeptidase | 0.0182 | 0.335 | 1 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0049 | 0.0028 | 0.5 |
Brugia malayi | STAT protein, DNA binding domain containing protein | 0.0159 | 0.2766 | 0.8258 |
Schistosoma mansoni | hypothetical protein | 0.0171 | 0.308 | 0.5025 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.0049 | 0.0028 | 0.0028 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0049 | 0.0028 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0049 | 0.0028 | 0.0046 |
Brugia malayi | prolyl oligopeptidase family protein | 0.0061 | 0.0325 | 0.0971 |
Echinococcus granulosus | histone acetyltransferase MYST2 | 0.0055 | 0.0167 | 0.0167 |
Echinococcus multilocularis | endonuclease exonuclease phosphatase | 0.019 | 0.3548 | 0.3548 |
Schistosoma mansoni | myelin transcription factor 1 myt1 | 0.0055 | 0.0167 | 0.0273 |
Brugia malayi | C2-HC type zinc finger protein C.e-MyT1 | 0.0055 | 0.0167 | 0.0499 |
Echinococcus multilocularis | geminin | 0.0171 | 0.308 | 0.308 |
Trypanosoma cruzi | serine peptidase, Clan SC, Family S9B | 0.0061 | 0.0325 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0055 | 0.0167 | 0.0499 |
Echinococcus multilocularis | suppression of tumorigenicity 18 protein | 0.0055 | 0.0167 | 0.0167 |
Onchocerca volvulus | Dipeptidyl peptidase family member 1 homolog | 0.0182 | 0.335 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 10 ug ml-1 | Antifungal activity against Cryptococcus neoformans assessed as 99.9 % growth inhibition after 18 hrs by zone-of-inhibition assay | ChEMBL. | 15270571 |
Activity (functional) | = 10 ug ml-1 | Antifungal activity against Saccharomyces cerevisiae assessed as 99.9 % growth inhibition after 18 hrs by zone-of-inhibition assay | ChEMBL. | 15270571 |
Activity (functional) | > 1000 ug ml-1 | Antimicrobial activity against Candida albicans assessed as 99.9 % growth inhibition after 18 hrs by zone-of-inhibition assay | ChEMBL. | 15270571 |
ED50 (functional) | = 0.3 ug ml-1 | Cytotoxicity against human KB cells | ChEMBL. | 15270571 |
ED50 (functional) | = 1.1 ug ml-1 | Cytotoxicity against human Lu1 cells | ChEMBL. | 15270571 |
ED50 (ADMET) | = 2.1 ug ml-1 | Cytotoxicity against human HUVEC | ChEMBL. | 15270571 |
ED50 (functional) | = 2.2 ug ml-1 | Cytotoxicity against human LNCAP cells | ChEMBL. | 15270571 |
IC50 (functional) | = 3 ug ml-1 | Antifungal activity against Cryptococcus neoformans after 18 hrs by zone-of-inhibition assay | ChEMBL. | 15270571 |
IC50 (functional) | = 3 ug ml-1 | Antifungal activity against Saccharomyces cerevisiae after 18 hrs by zone-of-inhibition assay | ChEMBL. | 15270571 |
IC50 (functional) | = 10 ug ml-1 | Antifungal activity against Candida albicans after 18 hrs by zone-of-inhibition assay | ChEMBL. | 15270571 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Cryptococcus neoformans | ChEMBL23 | 15270571 | |
Saccharomyces cerevisiae | ChEMBL23 | 15270571 | |
Candida albicans | ChEMBL23 | 15270571 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.